TWiV 298: MV-NIS de myelo

August 17, 2014

measles virus oncotherapyHosts: Vincent RacanielloAlan DoveRich Condit, and Kathy Spindler

The TWiV gang answers follow-up questions about the Ebola virus outbreak in West Africa, then discuss treatment of  disseminated multiple myeloma with oncolytic measles virus.

Click arrow to play
Download TWiV 298 (76 MB .mp3, 106 min)
Subscribe (free): iTunesRSSemail

Links for this episode

Weekly Science Picks

Alan – WTF, Evolution?! by Mara Grunbaum
Rich – Cold Spring Harbor Oral History Collection
Kathy – Inside insides
Vincent –
Going Viral (Rocky Mountain Ballet Theatre)

Listener Pick of the Week

Kim – Nobel Prize Podcasts
Johnye – The Planet is Fine
JennieCounter-Zombie Dominance Plan (pdf)

Send your virology questions and comments (email or mp3 file) to

Leave a Reply

Your email address will not be published. Required fields are marked *

2 comments on “TWiV 298: MV-NIS de myelo

  1. Mark Tomishima Aug 20, 2014

    Great show as always. To chime in on the massive dose used, I think it’s worth keeping three things in mind: 1) this isn’t a traditional inoculation. Here, you’re trying to productively infect all cancer cells in a person, far and wide. So I think it’s reasonable to assume you’ll need a massive dose to achieve a usable multiplicity in an entire person (note: some gene therapy trials have used over 10^13, so one might debate whether 10^11 is even high). Presumably, much of the virus is cleared since it doesn’t (physically) have access to CD46 [high] cells or might be titrated out by CD46 [normal] cells, plus there’s potential residual immunity as you mentioned. 2) This is a dose escalation trial to assess safety. Based on these early results, they might have undershot dose but this is likely all the FDA would allow. Maybe they can spread larger doses out over time to attenuate “cytokine storms”. 3) These patients have no other options. They are “astronauts” risking their lives but their lifespan and quality of life are limited without pushing the envelope. The patient with recurring disease is the likely outcome of under dosing. There are significant risks either way.

    Thanks for making the time to educate and entertain me during me soul-crushing commute. It’s much appreciated.

  2. Laila Gwinyai Aug 20, 2014

    Many thanks for answering my comments regarding the Ebola virus in your last podcast. I have family living just south of PR Congo (formerly Zaire) several of whom might appreciate sound, scientific information such as this. Thanks for taking the time to share what you know thus far.